back to US directory
us clinical guidance

Chronic kidney disease evaluation and management

KDIGO 2024 confirmation, GFR and albuminuria classification, progression risk, kidney-protective treatment and referral for US care.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with suspected or established chronic kidney disease (CKD), from detection through risk-based longitudinal care. KDIGO is a global guideline commonly used in US nephrology; this page does not replace disease-specific glomerular, transplant, dialysis, pregnancy or acute-kidney-injury guidance.
sources for this section:KDIGO CKD 2024

The Bottom Line

  • Confirm chronicity for at least three months when possible: CKD requires persistent reduced GFR or another marker of kidney damage, not a single creatinine or urine-albumin result obtained during acute illness.
  • Classify CKD by cause, GFR category and albuminuria category, and interpret eGFR together with urine albumin-to-creatinine ratio because each contributes independent prognostic information.
  • Use creatinine-based eGFR initially and add cystatin C in the situations identified by KDIGO when greater accuracy could alter diagnosis, drug dosing or another clinical decision.
  • Estimate kidney-failure risk with a validated equation in appropriate CKD populations and combine the result with progression, complications and patient goals when planning nephrology referral or kidney-replacement preparation.
  • Reduce kidney and cardiovascular risk through blood-pressure treatment, renin-angiotensin-system blockade for indicated albuminuria, an SGLT2 inhibitor when source criteria are met, lipid management, diabetes care, smoking treatment and avoidance of nephrotoxic exposure.
sources for this section:KDIGO CKD 2024

Practical clinical workflow

1
Repeat eGFR and urine albumin after an unexpected abnormality, review prior records for chronicity, and investigate hematuria, obstruction, systemic disease, family history and medicine or supplement exposure.
2
Assign cause, GFR and albuminuria categories; assess blood pressure, volume, diabetes, cardiovascular disease, anemia, potassium, bicarbonate and mineral-bone complications at a frequency matched to risk.
3
Calculate a validated kidney-failure risk where applicable, discuss prognosis without deterministic language, and use risk plus clinical features to determine follow-up and referral intensity.
4
Start or optimize kidney-protective treatment, checking contraindications and monitoring creatinine, potassium, volume and adverse effects after relevant changes.
5
Create a sick-day and medication-safety plan, reconcile every prescription and nonprescription product for kidney function, and prepare early for modality education when progression risk becomes substantial.
sources for this section:KDIGO CKD 2024

Safety boundaries and escalation

  • A rapid fall in eGFR, new oliguria, severe hyperkalemia, pulmonary edema, uremic features, suspected obstruction or systemic inflammatory disease requires urgent evaluation rather than routine CKD follow-up.
  • Do not stop renin-angiotensin-system or SGLT2 therapy solely because CKD is advanced; assess the specific acute change, hemodynamics, potassium, adverse effects and current source guidance.
  • Drug doses based on kidney function may require a measure different from the laboratory eGFR; consult the current FDA label and pharmacy guidance, especially near a dosing threshold.
  • Pregnancy, kidney transplantation, dialysis, nephrotic syndrome and suspected rapidly progressive glomerulonephritis follow specialist pathways with different treatment and safety rules.
sources for this section:KDIGO CKD 2024

Localization

KDIGO 2024 is international rather than a US federal guideline. Implement it with current FDA labeling, US laboratory reporting, local nephrology criteria and payer coverage.
sources for this section:KDIGO CKD 2024

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Kidney Disease: Improving Global OutcomesKDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseDOI 10.1016/j.kint.2023.10.018 路 published 2024-03-13 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.